Results 211 to 220 of about 35,703 (223)
Some of the next articles are maybe not open access.
Atherosclerosis, 2011
Proprotein convertase subtilisin kexin type 9 (PCSK9) is a circulating protein that impairs LDL clearance by promoting the LDL receptor (LDLR) degradation. PCSK9 has emerged as a new pharmacological target for hypercholesterolemia, and different PCSK9 inhibitors are now evaluated in clinical trials.
Cariou, Bertrand +2 more
openaire +3 more sources
Proprotein convertase subtilisin kexin type 9 (PCSK9) is a circulating protein that impairs LDL clearance by promoting the LDL receptor (LDLR) degradation. PCSK9 has emerged as a new pharmacological target for hypercholesterolemia, and different PCSK9 inhibitors are now evaluated in clinical trials.
Cariou, Bertrand +2 more
openaire +3 more sources
Targeting PCSK9 for Hypercholesterolemia
Annual Review of Pharmacology and Toxicology, 2014Dyslipidemias are a predominant risk factor for cardiovascular disease. Biological and genetic research has led to the identification of several genes and proteins that may be pharmacologically targeted to improve lipoprotein profiles and possibly cardiovascular outcomes in patients with dyslipidemia.
G.D. Norata, G. Tibolla, A.L. Catapano
openaire +3 more sources
Clinica Chimica Acta, 2015
Proprotein convertase subtilisin/kexin type 9 (PCSK9), a newly-recognized protein, plays a key role in regulating cholesterol homeostasis. PCSK9 reduces hepatic low-density lipoprotein receptors (LDLRs) thereby increasing LDL-cholesterol (LDL-C). Recently, biologic and genetic research proposed several approaches to inhibit or reduce PCSK9 to improve ...
Chuan-Jue Cui, Sha Li, Jian-Jun Li
openaire +2 more sources
Proprotein convertase subtilisin/kexin type 9 (PCSK9), a newly-recognized protein, plays a key role in regulating cholesterol homeostasis. PCSK9 reduces hepatic low-density lipoprotein receptors (LDLRs) thereby increasing LDL-cholesterol (LDL-C). Recently, biologic and genetic research proposed several approaches to inhibit or reduce PCSK9 to improve ...
Chuan-Jue Cui, Sha Li, Jian-Jun Li
openaire +2 more sources
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2008
Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a critical role in cholesterol metabolism by controlling the levels of low density lipoprotein (LDL) particles that circulate in the bloodstream. Several gain-of-function and loss-of-function mutations in the PCSK9 gene, that occur naturally, have been identified and linked to ...
openaire +2 more sources
Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a critical role in cholesterol metabolism by controlling the levels of low density lipoprotein (LDL) particles that circulate in the bloodstream. Several gain-of-function and loss-of-function mutations in the PCSK9 gene, that occur naturally, have been identified and linked to ...
openaire +2 more sources
Third generation PCSK9-inhibitors
European Heart Journal, 2023Ulrich Laufs +2 more
openaire +3 more sources
2013
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of circulating levels of lowdensity lipoprotein (LDL) particles. PCSK9 acts mainly by enhancing degradation of the LDL receptor in the liver. Several gain-of-function and loss-of-function mutations in the PCSK9 gene have been identified and linked to hypercholesterolemia and ...
openaire +1 more source
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of circulating levels of lowdensity lipoprotein (LDL) particles. PCSK9 acts mainly by enhancing degradation of the LDL receptor in the liver. Several gain-of-function and loss-of-function mutations in the PCSK9 gene have been identified and linked to hypercholesterolemia and ...
openaire +1 more source
2021
The invention relates to compounds with formula I: having inhibitory activity against the PCSK9 enzyme. Said compunds can be used, for example, in the prevention and/or treatment of dyslipidaemia.
Grazioso GIovanni +2 more
openaire +1 more source
The invention relates to compounds with formula I: having inhibitory activity against the PCSK9 enzyme. Said compunds can be used, for example, in the prevention and/or treatment of dyslipidaemia.
Grazioso GIovanni +2 more
openaire +1 more source